Delving into the Latest Updates on NEO-1940 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

CB1R x CB2

Mechanism

CB1 agonists(Cannabinoid CB1 receptor agonists), CB2 agonists(Cannabinoid CB2 receptor agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Anxiety DisordersCachexiaCancer Pain+ [2]

Inactive Indication

Low Back Pain

Originator Organization

Neomed Institute

Active Organization

Neomed Institute

Inactive Organization

AstraZeneca PLC

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC20H29F2N3O2S

InChIKeyZAGGGZCIFUQHOH-UHFFFAOYSA-N

CAS Registry881413-29-2

The primary aim of this study is to investigate if AZD1940 can relieve the pain induced by the surgical removal of one lower wisdom-tooth. This will be done by comparing the effect of AZD1940 to placebo ("inactive substance") on pain. A number of patients will instead receive the common painkiller naproxen for comparison purposes. Rescue medication, acetaminophen, will be allowed if a need for additional painkillers would arise. A number of patients will receive Naproxen as control.

Start Date01 Feb 2008

Sponsor / Collaborator

AstraZeneca PLC

100 Clinical Results associated with NEO-1940

Login to view more data

100 Translational Medicine associated with NEO-1940

Login to view more data

100 Patents (Medical) associated with NEO-1940

Login to view more data

4

Literatures (Medical) associated with NEO-1940

01 Jun 2022·British Journal of Oral and Maxillofacial SurgeryQ4 · MEDICINE

Cannabis and orofacial pain: a systematic review

Q4 · MEDICINE

Review

Author: Tan, H ; Gadiwalla, Y ; Grossman, S

The naturally occurring cannabis plant has played an established role in pain management throughout recorded history. However, in recent years, both natural and synthetic cannabis-based products for medicinal use (CBPM) have gained increasing worldwide attention due to growing evidence supporting their use in alleviating chronic inflammatory and neuropathic pain associated with an array of conditions. In view of these products' growing popularity in both the medical and commercial fields, we carried out a systematic review to ascertain the effects of cannabis and its synthetically derived products on orofacial pain and inflammation. The application of topical dermal cannabidiol formulation has shown positive findings such as reducing pain and improving muscle function in patients suffering from myofascial pain. Conversely, two orally-administered synthetic cannabinoid receptor agonists (AZD1940 and GW842166) failed to demonstrate significant analgesic effects following surgical third molar removal. There is a paucity of literature pertaining to the effects of cannabis-based products in the orofacial region; however, there is a wealth of high-quality evidence supporting their use for treating chronic nociceptive and neuropathic pain conditions in other areas. Further research is warranted to explore and substantiate the therapeutic role of CBPMs in the context of orofacial pain and inflammation. As evidence supporting their use expands, healthcare professionals should pay close attention to outcomes and changes to legislation that may impact and potentially benefit their patients.

01 Apr 2013·Nuclear Medicine and BiologyQ4 · MEDICINE

Radiolabeling of the cannabinoid receptor agonist AZD1940 with carbon-11 and PET microdosing in non-human primate

Q4 · MEDICINE

Article

Author: Katarina Varnäs ; Balázs Gulyás ; Magnus Schou ; Christer Halldin ; Lars Farde ; Aurelija Jucaite

INTRODUCTIONN-(2-tert-butyl-1-((4,4-difluorocyclohexyl)methyl)-1H-benzo[d]imidazol-5-yl)ethanesulfonamide (AZD1940) is a candidate drug for treatment of neuropathic pain. As part of the preclinical evaluation of AZD1940, a microdosing study with positron emission tomography (PET) was conducted to assess brain exposure.METHODSAZD1940 was radiolabeled with carbon-11 in the benzimidazole moiety. The radioactive precursor, lithium [(11)C]pivalate was obtained via (11)C-carboxylation of tert-butyl lithium. The target compound, [(11)C]AZD1940, was in turn obtained by the microwave assisted reaction between lithium [(11)C]pivalate and the o-phenylene diamine analog of AZD1940 (N-(3-amino-4-((4,4-difluorocyclohexyl)methylamino)phenyl)ethanesulfonamide) in neat phosphorous oxychloride. A brain PET measurement was performed in cynomolgus monkey.RESULTSThe overall radiochemical yield of final formulated radiochemically pure (>99%) [(11)C]AZD1940 was 0.4% (uncorrected for decay) and the specific radioactivity was 13GBq/μmol at time of administration (58min after end of bombardment). After intravenous injection to cynomolgus monkey, the maximum concentration of radioactivity detected in the brain region of interest was 0.7% of the total injected radioactivity. The regional distribution of radioactivity within brain was homogenous.CONCLUSIONSAZD1940 was radiolabelled with carbon-11 and its brain exposure, assessed using PET, was relatively low in comparison to peripheral organ exposure.

01 Jan 2013·Scandinavian Journal of Pain

Why we are proud to publish well-performed negative clinical studies?

Article

Author: Kalso, Eija ; Kontinen, Vesa

In the present issue of the Scandinavian Journal of Pain the aper “Evaluation of the analgesic efficacy of AZD1940, a novel annabinoid agonist, onpost-operative pain after lower thirdmolar xtraction” by Jarkko Kalliomaki et al. [1] describes the effect of peripherally active CB1/CB2-receptor agonist in the most comonly used model of postoperative pain. The compound is novel, he methodology is impeccable, the paper is very well written, and he topic is hot, and yet everyone in the business knows that it is ard to get it published. And this is only because the drug was not ffective. Most researchers have at some point struggled to publish negative study.

100 Deals associated with NEO-1940

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anxiety Disorders	Phase 1	-	Neomed Institute	-
Cachexia	Phase 1	-	Neomed Institute	-
Cancer Pain	Phase 1	-	Neomed Institute	-
Nausea	Phase 1	-	Neomed Institute	-
Sleep Initiation and Maintenance Disorders	Phase 1	-	Neomed Institute	-
Low Back Pain	Preclinical	SE	AstraZeneca PLC	01 Mar 2008
Pain	Preclinical	US	AstraZeneca PLC	01 Feb 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00659490 (CTgov)	Phase 2	Pain	151	AZD1940 (AZD1940)	yigiggmicx(bdiepemyah) = pgviffgpsq wlyjqfmhkt (cmcjobllwa, gqymbtspsj - crjssgqpge) View more	-	26 Mar 2012
				Placebo (Placebo)	yigiggmicx(bdiepemyah) = ymdtughcdf wlyjqfmhkt (cmcjobllwa, fvndveospo - mqlusxvewf) View more